Type VI secretion regulation: crosstalk and intracellular communication.

Curr Opin Microbiol

Department of Biology, Faculty of Natural and Applied Sciences, Trinity Western University, 7600 Glover Road, Langley, BC V2Y 1Y1, Canada.

Published: February 2011

Pathogens use type VI secretion systems (T6SSs) to transport proteins into the environment or host cells in response to external stimuli. T6SSs are tightly regulated together with other virulence determinants such as type III secretion systems, quorum sensing (QS), and flagella synthesis. Five pathogens (Salmonella enterica, Edwardsiella tarda, Aeromonas hydrophila, Vibrio cholerae, and Pseudomonas aeruginosa) are examined for crosstalk proteins (global regulators) that connect T6SSs to other virulence determinants. Common transcriptional regulators (TRs) include two component systems (i.e. PhoPQ), σ(54) and σ(54)-dependent TRs (i.e. VasH), and QS regulators. Greater understanding of this integral communication network will define what is essential for bacterial pathogenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mib.2010.09.017DOI Listing

Publication Analysis

Top Keywords

type secretion
8
secretion systems
8
virulence determinants
8
secretion regulation
4
regulation crosstalk
4
crosstalk intracellular
4
intracellular communication
4
communication pathogens
4
pathogens type
4
systems t6sss
4

Similar Publications

Comprehensive review of animal models in diabetes research using chemical agents.

Lab Anim

January 2025

Kastamonu University, Faculty of Medicine, Department of Physiology, Kastamonu, Turkey.

Diabetes mellitus, characterized by insufficient insulin secretion and impaired insulin efficacy, disrupts carbohydrate, protein, and lipid metabolism. The global diabetic population is expected to double by 2025, from 380 million, posing a significant health challenge. Most diabetic individuals fall into the type 1 or type 2 categories, and diabetes adversely affects various organs, such as the kidneys, liver, nervous system, reproductive system, and eyes.

View Article and Find Full Text PDF

Background: At present, the existing internal medicine drug treatment can alleviate the high glucose toxicity of patients to a certain extent, to explore the efficacy of laparoscopic jejunoileal side to side anastomosis in the treatment of type 2 diabetes, the report is as follows.

Aim: To investigate the effect of jejunoileal side-to-side anastomosis on metabolic parameters in patients with type 2 diabetes mellitus (T2DM).

Methods: We retrospectively analyzed the clinical data of 78 patients with T2DM who were treated jejunoileal lateral anastomosis.

View Article and Find Full Text PDF

Background: Epidemiological surveys indicate an increasing incidence of type 2 diabetes mellitus (T2DM) among children and adolescents worldwide. Due to rapid disease progression, severe long-term cardiorenal complications, a lack of effective treatment strategies, and substantial socioeconomic burdens, it has become an urgent public health issue that requires management and resolution. Adolescent T2DM differs from adult T2DM.

View Article and Find Full Text PDF

Current perspectives and the future of disease-modifying therapies in type 1 diabetes.

World J Diabetes

January 2025

Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Preston PR2 9HT, United Kingdom.

Use of immunomodulating agents to prevent the progression of autoimmune β-cell damage leading to type 1 diabetes mellitus (T1DM) is an interesting area for research. These include non-specific anti-inflammatory agents, immunologic vaccination and anti-inflammatory agents targeting specific immune cells or cytokines. Teplizumab is an anti-CD3-molecule that binds to and leads to the disappearance of the CD3/TCR complex and rendering the T cell anergic to its target antigen.

View Article and Find Full Text PDF

In this article, we review the study by Jin , which examined the role of intestinal glucagon-like peptide-1 (GLP-1) in counterregulatory responses to hypoglycemia in patients with type 1 diabetes mellitus (T1DM). With the global rise of T1DM, there is an increased burden on society and healthcare systems. Due to insulin therapy and islet dysfunction, T1DM patients are highly vulnerable to severe hypoglycemia, a leading cause of mortality.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!